Why We Chose It

At Project Healthspan we spend hundreds of hours evaluating every leading light therapy device on the market. Our bar is high, and the Vielight Neuro Duo is currently the only cognitive light therapy device to meet it. Vielight's publication record, device quality, and clinical trial presence put them in a category of their own. This is one of the few devices where the science and the product are fully aligned.

Most people using the Vielight Neuro Duo notice improvements in focus, clarity, and mood within six to eight weeks of consistent use.^{[1b.26][1b.28]} Some experience benefits sooner. Over time, many report that they can feel the shift a single session produces — the calm of Alpha mode or the sharp engagement of Gamma — which is part of what makes the device so practical for daily life. At Project Healthspan, we are proud to be partnered with Vielight — and more excited than ever to bring these tools to the people they can help.

The Bigger Picture

In clinical trials using the Mini-Mental State Examination (MMSE) — the gold standard cognitive assessment used in Alzheimer's research — tPBM produced average MMSE improvements of 2.6 to 4.8 points in patients with mild to moderately severe dementia.^{[1b.02][1b.25]} By comparison, donepezil (Aricept), the most widely prescribed Alzheimer's drug, averaged +1.73 MMSE points in a large 12-week global study of over 1,000 patients — while commonly causing nausea, vomiting, diarrhea, and cardiac side effects significant enough that 5% of patients discontinue it. The newest FDA-approved drug, lecanemab (Leqembi), does not improve MMSE scores at all; it modestly slows the rate of decline — while carrying risks of brain swelling, brain hemorrhage, and deaths in clinical trials, with 21.5% of participants experiencing amyloid-related imaging abnormalities.

Safety Profile

Cognitive Light Therapy has been studied across a wide range of populations with a consistently clean safety record. Across published clinical trials — including those in elderly dementia patients — no serious adverse events have been reported. The light is non-ionizing, non-thermal, and does not damage DNA or tissue.

One of the papers in our resource library describes tPBM's results as achieved "without the serious adverse effects associated with current leading Alzheimer's drugs."^[1b.02] The science does not yet support tPBM as a standalone treatment for neurodegenerative disease — larger trials are underway — but the contrast in both results and safety profile is something more people should know about. It is a significant part of why we built Project Healthspan.